{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:25:17Z","timestamp":1791325517517,"version":"4.3.1"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi241120-4\"><jats:title>Importance<\/jats:title><jats:p>Hepatitis C virus (HCV) microelimination aims to detect and treat hidden infections, especially in at-risk groups, like people experiencing homelessness (PEH) with alcohol or drug use disorders. Point-of-care HCV RNA testing and peer support workers are crucial for identifying and preventing HCV infection among marginalized populations, contributing to overall elimination goals.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241120-5\"><jats:title>Objective<\/jats:title><jats:p>To assess risk factors, prevalence, and trends of active HCV infection among PEH in Madrid, Spain (2019-2023).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241120-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This cross-sectional study was conducted between 2019 and 2023 in PEH, defined as people who lacked a fixed, regular, and adequate night residence, screened on the street or in homeless shelters via mobile unit using rapid HCV antibody testing, followed by HCV-RNA testing in Madrid, Spain. Data were analyzed from January to June 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241120-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Active HCV infection among PEH was the main outcome. Risk factors analyzed included being born outside of Spain, alcohol misuse, lacking financial income, benzodiazepine use, injection drug use (IDU; including nonactive IDU and active IDU within the last year), opioid substitution therapy participation, and sexual behavior patterns. Data were analyzed using logistic regression. <jats:italic>P<\/jats:italic> values were adjusted for multiple testing using the false discovery rate (<jats:italic>q<\/jats:italic>-values).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241120-8\"><jats:title>Results<\/jats:title><jats:p>A total of 4741 individuals were screened for HCV infection, of whom 2709 (mean [SD] age, 42.2 [12.7]; 1953 [72.2%] men) were PEH and included in analysis. A total of 363 PEH (13.4%) had test results positive for HCV antibodies, of whom 172 (47.4%) had test results positive for HCV-RNA, and 148 of these (91.9%) started HCV treatment. Overall, active HCV infection prevalence was 6.3%, and the main risk factors associated with active HCV infection included IDU, encompassing both nonactive IDU (adjusted odds ratio [aOR], 10.9; 95% CI, 6.1-19.4; <jats:italic>q<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) and active IDU in the last year (aOR, 27.0; 95% CI, 15.2-48.0; <jats:italic>q<\/jats:italic>\u2009&amp;amp;lt;\u2009.001); a lack of financial income (aOR, 1.8; 95% CI, 1.1-2.9; <jats:italic>q<\/jats:italic>\u2009=\u2009.03); and alcohol misuse (aOR, 1.8; 95% CI, 1.3-2.6; <jats:italic>q<\/jats:italic>\u2009=\u2009.008). There was a significant decrease between 2019 and 2023 in active HCV infection prevalence across the entire population, from 7.2% to 3.4% (<jats:italic>P<\/jats:italic>\u2009=\u2009.04).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241120-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cross-sectional study of PEH in Madrid, IDU, lack of income, and alcohol misuse were primary risk factors associated with HCV infection. The significant decline in HCV rates observed across all risk groups during the study period suggests preventive policies were effective in reducing HCV prevalence among the homeless population.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.38657","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T15:31:25Z","timestamp":1729870285000},"page":"e2438657","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of HCV Infection Among People Experiencing Homelessness in Madrid, Spain"],"prefix":"10.1001","volume":"7","author":[{"given":"Pablo","family":"Ryan","sequence":"first","affiliation":[{"name":"Hospital Universitario Infanta Leonor, Madrid, Spain"},{"name":"Universidad Complutense de Madrid, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Valencia","sequence":"additional","affiliation":[{"name":"Hospital Universitario Infanta Leonor, Madrid, Spain"},{"name":"Unidad de Reducci\u00f3n de Da\u00f1os Servicio M\u00f3vil de Atenci\u00f3n Sociosanitaria y Derivaci\u00f3n a tratamiento, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sep\u00falveda-Crespo","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Unidad de Infecci\u00f3n e Viral e Inmunidad, Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Amigot-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Unidad de Infecci\u00f3n e Viral e Inmunidad, Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Cuevas","sequence":"additional","affiliation":[{"name":"Hospital Universitario Infanta Leonor, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"Barcelona Institute for Global Health, Hospital Cl\u00ednic, University of Barcelona, Barcelona, Spain"},{"name":"Graduate School of Public Health and Health Policy, City University of New York, New York, New York"},{"name":"Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Servicio de Microbiolog\u00eda Cl\u00ednica, Hospital Universitario Pr\u00edncipe de Asturias, Madrid, Spain"},{"name":"Departamento de Biomedicina y Biotecnolog\u00eda, Facultad de Medicina, Universidad de Alcal\u00e1, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidoro","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Unidad de Infecci\u00f3n e Viral e Inmunidad, Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Resino","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Unidad de Infecci\u00f3n e Viral e Inmunidad, Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"issue":"10407","key":"zoi241120r1","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","article-title":"Hepatitis C.","volume":"402","author":"Martinello","year":"2023","journal-title":"Lancet"},{"key":"zoi241120r2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad319","article-title":"Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.","author":"Bhattacharya","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"3","key":"zoi241120r3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jhep.2019.04.017","article-title":"Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"71","author":"Ji","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"zoi241120r4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/joim.12972","article-title":"We know DAAs work, so now what: simplifying models of care to enhance the hepatitis C cascade.","volume":"286","author":"Lazarus","year":"2019","journal-title":"J Intern Med"},{"key":"zoi241120r6","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1093\/infdis\/jiac446","article-title":"HCV Microelimination for high-risk special populations.","volume":"228","author":"Huang","year":"2023","journal-title":"J Infect Dis"},{"issue":"5","key":"zoi241120r7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.","volume":"7","author":"Polaris Observatory HCV Collaborators","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"zoi241120r8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/liv.14779","article-title":"Progress towards hepatitis C virus elimination in high-income countries: an updated analysis.","volume":"41","author":"Gamkrelidze","year":"2021","journal-title":"Liver Int"},{"issue":"1","key":"zoi241120r9","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection.","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"issue":"6","key":"zoi241120r10","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/eurpub\/ckab069","article-title":"Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey.","volume":"31","author":"Estirado G\u00f3mez","year":"2021","journal-title":"Eur J Public Health"},{"issue":"5","key":"zoi241120r12","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.jhep.2018.06.016","article-title":"The removal of DAA restrictions in Europe\u2014one step closer to eliminating HCV as a major public health threat.","volume":"69","author":"Marshall","year":"2018","journal-title":"J Hepatol"},{"issue":"12","key":"zoi241120r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100580","article-title":"HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates.","volume":"4","author":"Lens","year":"2022","journal-title":"JHEP Rep"},{"issue":"5","key":"zoi241120r14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/diagnostics11050877","article-title":"Hepatitis C micro-elimination beyond prison walls: navigator-assisted test-and-treat strategy for subjects serving non-custodial sentences.","volume":"11","author":"Cabezas","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"zoi241120r15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.17235\/reed.2020.7194\/2020","article-title":"Linkage to care strategy for the micro-elimination of hepatitis C among parenteral drug users on methadone replacement therapy in Gipuzkoa.","volume":"112","author":"P\u00e9rez Casta\u00f1o","year":"2020","journal-title":"Rev Esp Enferm Dig"},{"issue":"11","key":"zoi241120r16","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/s41395-018-0157-x","article-title":"Microenvironment eradication of hepatitis C: A novel treatment paradigm.","volume":"113","author":"Cuadrado","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"zoi241120r17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S1473-3099(12)70177-9","article-title":"Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis.","volume":"12","author":"Beijer","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"zoi241120r18","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2468-2667(21)00013-X","article-title":"Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.","volume":"6","author":"Arum","year":"2021","journal-title":"Lancet Public Health"},{"issue":"2","key":"zoi241120r19","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S2468-2667(21)00258-9","article-title":"The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study.","volume":"7","author":"Stone","year":"2022","journal-title":"Lancet Public Health"},{"issue":"1","key":"zoi241120r20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/hex.13400","article-title":"Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: a mixed-methods systematic review.","volume":"25","author":"Paisi","year":"2022","journal-title":"Health Expect"},{"issue":"3","key":"zoi241120r21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0038-1666841","article-title":"The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations.","volume":"38","author":"Lazarus","year":"2018","journal-title":"Semin Liver Dis"},{"issue":"2","key":"zoi241120r22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"zoi241120r23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.14309\/ajg.0000000000002041","article-title":"Results of a model of delivering hepatitis C care in a homeless metropolitan population in England.","volume":"118","author":"Guerra-Veloz","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"zoi241120r24","doi-asserted-by":"publisher","DOI":"10.1177\/11782218221095871","article-title":"Hepatitis C virus prevalence, medical status awareness and treatment engagement among homeless people who use drugs: results of a street outreach study.","author":"Lasmanovich","year":"2022","journal-title":"Subst Abuse"},{"issue":"1","key":"zoi241120r25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/hep4.1791","article-title":"Shelter-based integrated model is effective in scaling up hepatitis C testing and treatment in persons experiencing homelessness.","volume":"6","author":"Khalili","year":"2022","journal-title":"Hepatol Commun"},{"issue":"4","key":"zoi241120r26","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1089\/pop.2020.0143","article-title":"Evaluation of risk factors for hepatitis c virus infection among Philadelphia\u2019s shelter-bound, homeless population: data from a student-run hepatitis C virus screening initiative.","volume":"24","author":"Leach","year":"2021","journal-title":"Popul Health Manag"},{"key":"zoi241120r27","doi-asserted-by":"publisher","first-page":"S342","DOI":"10.1093\/infdis\/jiad463","article-title":"Molecular point-of-care testing for hepatitis C: available technologies, pipeline, and promising future directions.","volume":"229","author":"Ivanova Reipold","year":"2024","journal-title":"J Infect Dis"},{"key":"zoi241120r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103424","article-title":"Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain.","volume":"96","author":"Ryan","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"29","key":"zoi241120r29","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.29.2300712","article-title":"Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study.","volume":"29","author":"Ryan","year":"2024","journal-title":"Euro Surveill"},{"issue":"2","key":"zoi241120r30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"zoi241120r31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"issue":"6","key":"zoi241120r32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/hep4.1731","article-title":"Key elements on the pathway to hcv elimination: lessons learned from the AASLD HCV Special Interest Group 2020.","volume":"5","author":"Feld","year":"2021","journal-title":"Hepatol Commun"},{"issue":"9","key":"zoi241120r33","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S2468-1253(20)30238-7","article-title":"The impact of COVID-19 on hepatitis elimination.","volume":"5","author":"Wingrove","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"zoi241120r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100531","article-title":"Impact of the COVID-19 pandemic on hepatitis B and C elimination: an EASL survey.","volume":"4","author":"Kondili","year":"2022","journal-title":"JHEP Rep"},{"issue":"3","key":"zoi241120r35","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016.","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"zoi241120r36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cld.1098","article-title":"Evaluation of hepatitis C test and treat interventions targeted at homeless populations (outside London) in England during the COVID-19 pandemic.","volume":"17","author":"Wilkinson","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"5","key":"zoi241120r37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268841","article-title":"Comorbidity profiles of patients experiencing homelessness: a latent class analysis.","volume":"17","author":"Subedi","year":"2022","journal-title":"PLoS One"},{"issue":"2","key":"zoi241120r38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/eurpub\/cky142","article-title":"Hepatitis C prevalence and associated risk factors among individuals who are homeless and diagnosed with mental illness: at Home\/Chez Soi Study, Vancouver, BC.","volume":"29","author":"Nikoo","year":"2019","journal-title":"Eur J Public Health"},{"issue":"2","key":"zoi241120r39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1046\/j.1525-1497.2002.10415.x","article-title":"Risk factors for hepatitis C virus infection among homeless adults.","volume":"17","author":"Nyamathi","year":"2002","journal-title":"J Gen Intern Med"},{"issue":"3","key":"zoi241120r40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.drugalcdep.2013.03.009","article-title":"The longitudinal association between homelessness, injection drug use, and injection-related risk behavior among persons with a history of injection drug use in Baltimore, MD.","volume":"132","author":"Linton","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"zoi241120r41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/003335491212700409","article-title":"Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in Los Angeles.","volume":"127","author":"Gelberg","year":"2012","journal-title":"Public Health Rep"},{"issue":"4","key":"zoi241120r42","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jhep.2015.06.014","article-title":"Excluding people who use drugs or alcohol from access to hepatitis C treatments\u2014is this fair, given the available data?","volume":"63","author":"Grebely","year":"2015","journal-title":"J Hepatol"},{"key":"zoi241120r43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.drugpo.2017.05.054","article-title":"Restrictions on access to direct-acting antivirals for people who inject drugs: the European Hep-CORE study and the role of patient groups in monitoring national HCV responses.","volume":"47","author":"Lazarus","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi241120r44","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jhep.2013.03.007","article-title":"Global burden of alcoholic liver diseases.","volume":"59","author":"Rehm","year":"2013","journal-title":"J Hepatol"},{"issue":"11","key":"zoi241120r45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039724","article-title":"The Copenhagen test and treat hepatitis C in a mobile clinic study: a protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (T\u2019N\u2019T HepC).","volume":"10","author":"Lazarus","year":"2020","journal-title":"BMJ Open"},{"key":"zoi241120r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103134","article-title":"HCV screening based on dried blood samples and linkage to care in people who use drugs: a prospective study.","volume":"92","author":"Ryan","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi241120r47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s43856-023-00292-y","article-title":"Combined COVID-19 vaccination and hepatitis C virus screening intervention in marginalised populations in Spain.","volume":"3","author":"Lazarus","year":"2023","journal-title":"Commun Med (Lond)"},{"issue":"6","key":"zoi241120r48","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S2468-1253(23)00018-3","article-title":"Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis.","volume":"8","author":"Artenie","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"zoi241120r49","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep4.1492","article-title":"Recommendations for implementing hepatitis C virus care in homeless shelters: the stakeholder perspective.","volume":"4","author":"Fokuo","year":"2020","journal-title":"Hepatol Commun"},{"issue":"9","key":"zoi241120r50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012021.pub2","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.","volume":"9","author":"Platt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"zoi241120r51","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"key":"zoi241120r52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.drugpo.2017.02.006","article-title":"Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals.","volume":"47","author":"Mah","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi241120r53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12916-019-1300-2","article-title":"Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention.","volume":"17","author":"Stagg","year":"2019","journal-title":"BMC Med"},{"issue":"2","key":"zoi241120r54","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/0033354916689610","article-title":"Engagement in the hepatitis C care cascade among homeless veterans, 2015.","volume":"132","author":"Noska","year":"2017","journal-title":"Public Health Rep"},{"key":"zoi241120r5","unstructured":"World Health Organization GHHaSPH. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Accessed September 5, 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240053779"},{"key":"zoi241120r11","unstructured":"Ministry of Health, Social Services and Equality. Strategic plan for tackling hepatitis C in the Spanish National Health System. Accessed September 5, 2024. https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/hepatitisC\/PlanEstrategicoHEPATITISC\/docs\/PEAHC_eng.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2825346\/ryan_2024_oi_241120_1729266944.04255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T15:31:28Z","timestamp":1729870288000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2825346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.38657","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}